A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-Diabetic Drug.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-Diabetic Drug.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SYMPHONY
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Jul 2009 Actual patient number (458) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top